We are live on ! Find out more
ACM

Aisling Capital Management Portfolio holdings

AUM $476M
1-Year Est. Return 128.63%
This Fund
S&P 500
This Quarter Est. Return
+4.96%
1 Year Est. Return
+128.63%
3 Year Est. Return
+700.94%
5 Year Est. Return
+846.44%
10 Year Est. Return
–
AUM
$313M
AUM Growth
+$51M
Cap. Flow
+$48.7M
Cap. Flow %
15.57%
Top 10 Hldgs %
96.69%
Holding
15
New
2
Increased
1
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
HRMY icon
Harmony Biosciences
HRMY
+$30.7M
2
PSTX
Poseida Therapeutics, Inc. Common Stock
PSTX
+$11.9M
3
VRNA
Verona Pharma
VRNA
+$6.14M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BBIO icon
1
BridgeBio Pharma
BBIO
$15.7B
$150M 47.82%
3,989,412
– –
EIDX
2
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$56.8M 18.14%
1,123,630
– –
HRMY icon
3
Harmony Biosciences
HRMY
$2.04B
$28.6M 9.13%
+842,815
New +$30.7M
SNDX icon
4
Syndax Pharmaceuticals
SNDX
$1.69B
$15.1M 4.83%
1,025,000
– –
TECX
5
Tectonic Therapeutic
TECX
$529M
$13.1M 4.2%
84,148
– –
SYRE icon
6
Spyre Therapeutics
SYRE
$8.54B
$12M 3.83%
67,646
– –
PSTX
7
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$9.25M 2.96%
+1,043,267
New +$11.9M
VRNA
8
DELISTED
Verona Pharma
VRNA
$8.31M 2.66%
1,332,485
+888,889
+200% +$6.14M
BCEL
9
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$5.42M 1.73%
387,653
– –
ZSAN
10
DELISTED
Zosano Pharma Corporation
ZSAN
$4.4M 1.41%
77,664
– –
OBSV
11
DELISTED
ObsEva SA Ordinary Shares
OBSV
$3.44M 1.1%
1,386,338
– –
MRKR icon
12
Marker Therapeutics
MRKR
$18.8M
$3M 0.96%
200,000
– –
ACRS icon
13
Aclaris Therapeutics
ACRS
$726M
$1.63M 0.52%
634,455
– –
VIRX
14
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$1.26M 0.4%
288,571
– –
NBRV
15
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$1.02M 0.33%
7,641
– –

Similar funds

BF
Brooklyn FI New York $476M AUM 17.97% 1-Year Est. Return
VIA
Vickerman Investment Advisors Spokane, Washington $476M AUM 12.21% 1-Year Est. Return
DE
Devon Energy Houston, Texas $476M AUM
FAM
Frontier Asset Management Sheridan, Wyoming $477M AUM 19.41% 1-Year Est. Return
BHWA
Beacon Harbor Wealth Advisors Virginia Beach, Virginia $477M AUM 49.25% 1-Year Est. Return
AL4A
Accel Leaders 4 Associates Palo Alto, California $475M AUM 391.52% 1-Year Est. Return
LEFP
Leading Edge Financial Planning Knoxville, Tennessee $475M AUM 15.22% 1-Year Est. Return
MVP
Medina Value Partners Los Angeles, California $477M AUM 25.52% 1-Year Est. Return

Aisling Capital Management's Q3 2020 Portfolio in Review

As of Q3 2020, Aisling Capital Management held 15 positions worth $313M, up 19% from $262M the previous quarter. Its ten largest holdings account for 97% of the portfolio.

Aisling Capital Management deployed $48.7M of net new capital in Q3 2020, opening 2 new positions and adding to 1 existing holding. Its largest new stake was Harmony Biosciences: 842,815 shares worth $28.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Aisling Capital Management's largest Q3 2020 buy was Harmony Biosciences: 842,815 shares worth $28.6M.
  • Aisling Capital Management added most to Verona Pharma in Q3 2020, an estimated $6.14M increase.
  • Aisling Capital Management's ten largest holdings make up 97% of its $313M portfolio in Q3 2020.
  • Aisling Capital Management opened 2 new positions and closed 0 in Q3 2020.
  • Aisling Capital Management's portfolio value rose 19% quarter-over-quarter to $313M.

Based on Aisling Capital Management's 13F filing for Q3 2020, filed 12 Nov 2020.